Implementation of the Methylome in the Characterization of Solid Tumors
NCT07268066 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180
Last updated 2025-12-18
Summary
This study aims to investigate the functional consequences of specific methylation changes and to examine the clinical implications of these alterations. Methylation analysis is a powerful tool for understanding the molecular mechanisms of brain tumors and other solid tumors and can help identify new diagnostic and therapeutic targets. By analyzing DNA methylation patterns in tumor tissue, it is possible to identify genes that are silenced or activated by methylation. This information can be used to develop new biomarkers for early diagnosis and to identify new therapeutic targets that can be used to reverse methylation-mediated gene silencing.
Conditions
- Solid Tumor Cancer
Sponsors & Collaborators
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-21
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Italy
Study Locations
More Related Trials
-
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
NCT01919749 ·Status: COMPLETED ·Phase: NA
-
GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers
NCT06076070 ·Status: UNKNOWN
-
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
NCT04264767 ·Status: COMPLETED
-
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
NCT05685524 ·Status: UNKNOWN
-
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
NCT01334008 ·Status: COMPLETED ·Phase: NA
-
Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma
NCT06912672 ·Status: NOT_YET_RECRUITING
-
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
NCT06863870 ·Status: ACTIVE_NOT_RECRUITING
-
The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors
NCT07132606 ·Status: NOT_YET_RECRUITING
-
ctDNA Methylation Sequencing for Myeloma
NCT05578625 ·Status: UNKNOWN
-
The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor
NCT06863844 ·Status: RECRUITING
-
S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia
NCT01434329 ·Status: COMPLETED
-
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663 ·Status: COMPLETED
-
Detection of G-quadruplex DNA Methylation in Cancer
NCT06537063 ·Status: WITHDRAWN
-
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
NCT05480644 ·Status: RECRUITING
-
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
NCT04628806 ·Status: UNKNOWN
-
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
NCT05888636 ·Status: RECRUITING
-
Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis
NCT03029065 ·Status: UNKNOWN
-
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma
NCT05344027 ·Status: COMPLETED
-
UWCCC Molecular Tumor Board Registry
NCT03023202 ·Status: RECRUITING
-
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106 ·Status: RECRUITING
-
Epigenetic Changes in Head and Neck Cancer
NCT04260074 ·Status: COMPLETED
-
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer
NCT02079363 ·Status: UNKNOWN
-
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients
NCT02626039 ·Status: COMPLETED
-
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
NCT05758948 ·Status: UNKNOWN
-
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
NCT06905262 ·Status: RECRUITING